ArticleInfection and immunity1999
Phage-displayed T-cell epitope grafted into immunoglobulin heavy-chain complementarity-determining regions: an effective vaccine design tested in murine cysticercosis.
Article in Infection and immunity, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 35 citations in OpenAlex.
- Immunogenic properties of immunoglobulin superfamily members within complex biological networks.Cellular immunology · 2020Review
- Mimotope-based antigens as potential vaccine candidates in experimental murine cysticercosis.Parasitology · 2020Article
- Thermoresponsive Bacteriophage Nanocarrier as a Gene Delivery Vector Targeted to the Gastrointestinal Tract.Molecular therapy. Nucleic acids · 2018Article
- Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8Immunologic research · 2018Article
- Bacteriophages and their applications in the diagnosis and treatment of hepatitis B virus infection.World journal of gastroenterology · 2014Review
- Therapeutic and prophylactic applications of bacteriophage components in modern medicine.Cold Spring Harbor perspectives in medicine · 2014Review
- Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.PloS one · 2014Article
- Isolation of antibodies specific to a single conformation-dependant antigenic determinant on the EG95 hydatid vaccine.Vaccine · 2009Article
- Filamentous phage as an immunogenic carrier to elicit focused antibody responses against a synthetic peptide.Vaccine · 2006Article
- Detection of HLA class II-dependent T helper antigen using antigen phage display.Clinical and experimental immunology · 2004Article
- Macrophage migration inhibitory factor plays a critical role in mediating protection against the helminth parasite Taenia crassiceps.Infection and immunity · 2003Article
- Characterization and protective potential of the immune response to Taenia solium paramyosin in a murine model of cysticercosis.Infection and immunity · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new type of immunogenic molecule was engineered by replacing all three complementarity-determining-region (CDR) loops of the human immunoglobulin (Ig) heavy-chain variable (V(H)) domain with the Taenia crassiceps epitope PT1 (PPPVDYLYQT) and by displaying this construct on the surfaces of M13 bacteriophage. When BALB/c mice were immunized with such phage particles (PIgphage), a strong protection against challenge infection in very susceptible female hosts was obtained. When specifically stimulated, the in vivo-primed CD4(+) and CD8(+) T cells isolated from mice immunized with PT1, both as a free peptide and as the PIgphage construct, proliferated in vitro, indicating efficient epitope presentation by both major histocompatibility complex class II and class I molecules in the specifically antigen-pulsed macrophages used as antigen-presenting cells. These data demonstrate the immunogenic potential of recombinant phage particles displaying CDR epitope-grafted Ig V(H) domains and establish an alternative approach to the design of an effective subunit vaccine for prevention of cysticercosis. The key advantage of this type of immunogen is that no adjuvant is required for its application. The proposed strategy for immunogen construction is potentially suitable for use in any host-pathogen interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.